Risk factor
Strong trading liquidity
Profitability factor
Good margins and returns
About
Shenzhen YHLO Biotech Co., Ltd. engages in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents in China. It offers clinical solutions for autoimmune, reproductive health, infectious, and other diseases; CLIA test panels, chemiluminescence immunoassay analyzers, and integration systems for immunoassay; ELISA test panels and immune analyzers; LIA test panels, blot analyzers, and line immunoassays; POCT test panels and immunofluorescence readers; ESR Analyzers; and COVID-19 detection kits. The company also exports its COVID-19 detection kits to various countries, including Germany, France, Italy, Denmark, Sweden, etc. Shenzhen YHLO Biotech Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expens
Buy
Sell